Abstract: A method for effectively suppressing GVHD, which occurs after peripheral blood stem cells allotransplantation, without causing marked side effects, and a pharmaceutical composition intended for this purpose and containing human G-CSF as an active ingredient. GVHD can be suppressed by administering human G-CSF to a transplantation recipient after peripheral blood stem cells transplantation.
Abstract: Disclosed is a therapeutic method for inhibiting development or growth of tumors that are resistant to the blockade of delta-like ligand 4 (Dll4), or vascular endothelial growth factor (VEGF), or to other therapeutic agents, by administering the combination of Dll4 antagonist and VEGF antagonist. The combined administration of these two agents, concurrently or sequentially, exhibits synergistic effects on blood vessel development and growth, thereby more effectively inhibiting the tumor growth than an administration of either agent alone. The Dll4 antagonist can be an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch receptor, or a fusion protein comprising the extracellular domain of Dll4 or a soluble Notch receptor, or a fragment thereof, fused to a multimerizing component. The VEGF antagonist can be a VEGF trap, anti-VEGF antibody or antibody fragment capable of inhibiting the binding of VEGF to a VEGF receptor.
Type:
Grant
Filed:
May 4, 2009
Date of Patent:
November 1, 2011
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Irene Noguera-Troise, Gavin Thurston, Nicholas Gale, Eric Smith
Abstract: The invention relates to the method for treatment, diagnosis and prevention of diseases related to fetal growth and placental insufficiency and comprises methods including inhibiting or increasing relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, and relaxin receptor activity. The invention also relates to screening assays to identify compounds that modulate relaxin and/or relaxin receptor activity. The invention further relates to gene therapy methods utilizing relaxin and relaxin-related sequences for the treatment and prevention of diseases related to fetal growth and placental insufficiency.
Abstract: It is an object of the present invention to provide a composition for promoting the production of type I collagen by human skin fibroblasts, and the present invention relates to a composition for promoting type I collagen production containing silybin and a peptide that promotes collagen production (peptide having an amino acid sequence of Gly-Pro-Hyp, Gly-His-Lys, Lys-Thr-Thr-Lys-Ser (SEQ ID NO: 1) or Gly-Glu-Pro-Arg (SEQ ID NO: 2).
Abstract: The present invention relates to the inhibition of angiogenesis by neutrophil alpha-defensins. Further, the present invention relates to methods involving the inhibition of endothelial cell adhesion to the extracellular matrix, endothelial cell apoptosis, and endothelial cell angiogenesis mediated by alpha-defensins.
Type:
Grant
Filed:
October 8, 2008
Date of Patent:
August 16, 2011
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
Douglas Cines, Khalil Bdeir, Klaus T. Preissner, Triantafylios Chavakis
Abstract: The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.
Type:
Grant
Filed:
February 28, 2003
Date of Patent:
June 21, 2011
Assignee:
Human Genome Sciences, Inc.
Inventors:
Reinhard Ebner, Guo-Liang Yu, Steven M Ruben, Yifan Zhai, Stephen Ullrich
Abstract: The invention relates to compounds that include peptides that inhibit estrogen receptor dependent cell proliferation. The compounds of the invention are useful for treating cell proliferative disorders or physiological conditions characterized by undesirable or unwanted estrogen induced cell proliferation, including breast cancer.
Type:
Grant
Filed:
March 25, 2009
Date of Patent:
June 21, 2011
Assignee:
Albany Medical College
Inventors:
Thomas T. Andersen, James A. Bennett, Herbert Jacobson
Abstract: The invention relates to methods and kits for detecting enzyme activity using bioluminescence. In particular, it relates to a novel assay system with increased light yield for a sensitive and convenient detection of luciferase activity, such as luciferase reporter enzyme activity. Provided is a method of detecting luciferase activity in a sample, comprising incubating the sample in the presence of luciferin and ATP to allow the generation of a light signal, wherein said light signal is enhanced by performing the incubation in a reaction mixture comprising phosphate and ammonium ions, and measuring the light signal. The invention also relates to kits for use in such method.
Type:
Grant
Filed:
April 8, 2008
Date of Patent:
May 31, 2011
Assignee:
PerkinElmer Life and Analytical Sciences B.V.
Abstract: Disclosed herein are methods for diagnosing pre-eclampsia and eclampsia. Also disclosed herein are methods for treating pre-eclampsia and eclampsia using compounds that increase VEGF or PlGF levels or compounds that decrease sFlt-1 levels. Compounds that inhibit the binding of VEGF or PlGF to sFlt1- are also disclosed herein for the treatment of pre-eclampsia or eclampsia.
Type:
Grant
Filed:
August 4, 2008
Date of Patent:
May 24, 2011
Assignee:
Beth Israel Deaconess Medical Center
Inventors:
S. Ananth Karumanchi, Sharon Maynard, Vikas P. Sukhatme
Abstract: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.
Type:
Grant
Filed:
December 8, 2006
Date of Patent:
May 10, 2011
Assignee:
MedImmune Limited
Inventors:
Olivia Raeber, Gadi Gazit-Bornstein, Xiaodong Yang, Susan Ann Cartlidge, David William Tonge
Abstract: The present invention relates to nucleotide sequences of vertebrate Delta genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the vertebrate Delta protein is a human protein. The invention further relates to fragments (and derivatives and analogs thereof) of Delta which comprise one or more domains of the Delta protein, including but not limited to the intracellular domain, extracellular domain, DSL domain, domain amino-terminal to the DSL domain, transmembrane region, or one or more EGF-like repeats of a Delta protein, or any combination of the foregoing. Antibodies to Delta, its derivatives and analogs, are additionally provided. Methods of production of the Delta proteins, derivatives and analogs, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are provided.
Type:
Grant
Filed:
July 24, 2006
Date of Patent:
April 19, 2011
Assignees:
Yale Universtiy, Imperial Cancer Research Foundation, Ltd.
Inventors:
David Ish-Horowicz, Domingos Manuel Pinto Henrique, Julian Hart Lewis, Spyridon Artavanis-Tsakonas, Grace E. Gray
Abstract: A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates.
Type:
Grant
Filed:
August 3, 2007
Date of Patent:
April 19, 2011
Assignee:
Mountain View Pharmaceuticals, Inc.
Inventors:
Merry R. Sherman, Mark G. P. Saifer, L. David Williams, Michael S. Hershfield, Susan J. Kelly
Abstract: Human CTLA-8 protein, antibodies that specifically bind to human CTLA-8, and nucleic acids encoding human CTLA-8. Methods of using these molecules and diagnostic kits are also provided.
Type:
Grant
Filed:
October 31, 2007
Date of Patent:
February 1, 2011
Assignees:
Schering Corporation, Institut National de la Sante Et de la Recherche Medicale (INSERM)
Inventors:
Pierre Golstein, Eric Rouvier, Francois Fossiez, Serge J. E. Lebecque, Odile Djossou, Jacques F. Banchereau
Abstract: The present invention relates to CSF3R polypeptide variants and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as well as methods and tools for detecting or dosing these polypeptides in any sample.
Abstract: The present invention provides, for the first time, nucleic acids encoding a eukaryotic mechanosensory transduction channel (MSC) protein. The proteins encoded by these nucleic acids form channels that can directly detect mechanical stimuli and convert them into electrical signals. These nucleic acids and the proteins they encode can be used as probes for sensory cells in animals, and can be used to diagnose and treat any of a number of human conditions involving inherited, casual, or environmentally-induced loss of mechanosensory transduction activity.
Type:
Grant
Filed:
February 6, 2007
Date of Patent:
January 11, 2011
Assignee:
The Regents of the University of California
Inventors:
Charles S. Zuker, Richard G. Walker, Aarron Willingham
Abstract: Disclosed herein are methods for diagnosing pre-eclampsia and eclampsia. Also disclosed herein are methods for treating pre-eclampsia and eclampsia using compounds that increase VEGF or PlGF levels or compounds that decrease sFlt-1 levels. Compounds that inhibit the binding of VEGF or PlGF to sFlt1—are also disclosed herein for the treatment of pre-eclampsia or eclampsia.
Type:
Grant
Filed:
February 12, 2008
Date of Patent:
December 7, 2010
Assignee:
Beth Israel Deaconess Medical Center
Inventors:
S. Ananth Karumanchi, Sharon Maynard, Vikas P. Sukhatme
Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1.
Type:
Grant
Filed:
June 6, 2008
Date of Patent:
November 23, 2010
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
David J. Glass, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
Abstract: Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant of human serum albumin, methods for preparation, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing fusion polypeptides.
Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.
Type:
Grant
Filed:
April 17, 2008
Date of Patent:
November 9, 2010
Assignee:
Allozyne, Inc.
Inventors:
Kenneth H. Grabstein, Aijun Wang, Natalie Winblade Nairn, Thomas James Graddis